V
48.44
-3.95 (-7.54%)
| Previous Close | 52.39 |
| Open | 52.93 |
| Volume | 1,619,626 |
| Avg. Volume (3M) | 1,376,565 |
| Market Cap | 6,994,623,488 |
| Price / Book | 2.28 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2026 |
| Diluted EPS (TTM) | -3.99 |
| Total Debt/Equity (MRQ) | 2.72% |
| Current Ratio (MRQ) | 17.70 |
| Operating Cash Flow (TTM) | -459.78 M |
| Levered Free Cash Flow (TTM) | -419.13 M |
| Return on Assets (TTM) | -14.53% |
| Return on Equity (TTM) | -19.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Vaxcyte, Inc. | Bullish | Bearish |
AIStockmoo Score
0.9
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | 0.88 |
|
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.68% |
| % Held by Institutions | 117.40% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |